Global Heart Failure Therapeutics Market Size Study, by Treatment, by Type, by Stage, by End User, and Regional Forecasts 2022-2032

Description

The Global Heart Failure Therapeutics Market is valued at approximately USD 23.98 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 10.46% over the forecast period 2024-2032. Heart failure therapeutics are observing an upward trajectory, spurred by an aging population increasingly susceptible to cardiac conditions. Advances in medical technology are enhancing treatment and management of heart failure, while rising income levels and health awareness in developing economies are leading to greater healthcare expenditure. The demand for sophisticated treatments continues to climb, driven by a population eager for high-quality care, prompting governments and private entities to boost investment in research and development (R&D). Amidst these growth factors lie considerable opportunities; the pharmaceutical and biotech industries are poised to unveil cutting-edge drugs and biological solutions, with digital health tools, such as patient monitoring and analytics, poised to redefine care standards. Strategic alliances are forming across the sector, combining the innovation of biotech start-ups with the reach of established pharmaceutical companies, and the movement towards personalized medicine opens doors to highly individualized therapies.

The Global Heart Failure Therapeutics Market is experiencing robust growth, propelled by several key factors. The escalating prevalence of chronic diseases, coupled with the pressing need for more accurate models to study disease progression and develop targeted therapies, is driving the demand for advanced heart failure therapeutics. For instance, significant investments exceeding USD 300 billion have been granted to various institutes by leading manufacturers, universities, nonprofit organizations, and the federal government. This funding aims to foster the development of scalable manufacturing processes for engineered tissues and organs, reflecting the industry's commitment to advancing heart failure therapeutic technologies. However, this market faces regulatory complexities and reimbursement challenges. The steep costs associated with R&D and therapeutic solutions can hinder market growth. Further obstructions include the underdiagnosis and unawareness of heart failure in some regions, the expiration of key drug patents leading to generic competition, and the ongoing issue of patient adherence to treatment and lifestyle regimes.

The key regions considered for the global heart failure therapeutics market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in the marketplace. The regional market growth is propelled by the presence of key players such as Abbott Laboratories and Johnson & Johnson, alongside advancements in the manufacturing technology of heart failure therapeutics. Furthermore, the region has well-established healthcare infrastructure and substantial investment in research and development (R&D), fostering an environment conducive to the advancement and adoption of cutting-edge technologies like heart failure therapeutics. These factors collectively drive market growth, positioning the region as a hub for innovation and development in the field of heart failure therapeutics. The market in Asia Pacific, on the other hand, is expected to grow at the fastest rate over the forecast period, driven by significant shifts in heart failure treatment demands.

Major market players included in this report are:

Abbott Laboratories
ABIOMED, Inc.
Alembic Pharmaceuticals Limited
Amgen Inc.
AstraZeneca PLC
Bayer AG
Beckman Coulter, Inc.
Berlin Heart GmbH
Biosensors International Group, Ltd.
Biotronik SE & Co. KG
Boston Scientific Corporation
Bristol-Myers Squibb Company
Cardiol Therapeutics Inc.
Cipla Limited
Dr. Reddy's Laboratories Limited

The detailed segments and sub-segment of the market are explained below:

By Treatment:

Medical Devices
- Bi-level Positive Air Pressure Device
- Biventricular Pacemaker
- Continuous Positive Air Pressure Device
- Heart Pumps
- Implantable Cardioverter-Defibrillators
- Implantable Left Ventricular Assist Device
Medicines
- Angiotensin II Receptor Blockers
- Anticoagulant Medicines
- Antiplatelet Medicines
- Blood Pressure Maintaining Agents
- Diuretics
- Nitrates
- Statins
Surgery
- Cardiac Resynchronization
- Coronary Artery Bypass Grafting
- Coronary Revascularization
- Heart Transplant
- Heart Valve Replacement

By Type:

Diagnosis
Prognosis

By Stage:

Stage A
Stage B
Stage C
Stage D

By End User:

Clinic
Hospital
Medical Research Organization

By Region: North America

U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows: Historical year - 2022 Base year - 2023 Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Heart Failure Therapeutics Market Executive Summary

1.1. Global Heart Failure Therapeutics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Treatment
- 1.3.2. By Type
- 1.3.3. By Stage
- 1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Heart Failure Therapeutics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Heart Failure Therapeutics Market Dynamics

3.1. Market Drivers
- 3.1.1. Aging population and rising prevalence of heart failure
- 3.1.2. Advancements in medical technology and treatment options
- 3.1.3. Increased healthcare expenditure in developing economies
3.2. Market Challenges
- 3.2.1. Regulatory complexities and reimbursement issues
- 3.2.2. High R&D costs and therapeutic solution expenses
- 3.2.3. Underdiagnosis and unawareness in certain regions
3.3. Market Opportunities
- 3.3.1. Development of gene and stem cell therapies
- 3.3.2. Integration of AI and machine learning in diagnostics
- 3.3.3. Growth in remote patient monitoring and digital health tools

Chapter 4. Global Heart Failure Therapeutics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Heart Failure Therapeutics Market Size & Forecasts by Treatment 2022-2032

5.1. Segment Dashboard
5.2. Global Heart Failure Therapeutics Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Medical Devices
  - 5.2.1.1. Bi-level positive air pressure device
  - 5.2.1.2. Biventricular Pacemaker
  - 5.2.1.3. Continuous Positive Air Pressure Device
  - 5.2.1.4. Heart Pumps
  - 5.2.1.5. Implantable Cardioverter-Defibrillators
  - 5.2.1.6. Implantable Left Ventricular Assist Device
- 5.2.2. Medicines
  - 5.2.2.1. Angiotensin II Receptor Blockers
  - 5.2.2.2. Anticoagulant Medicines
  - 5.2.2.3. Antiplatelet Medicines
  - 5.2.2.4. Blood Pressure Maintaining Agents
  - 5.2.2.5. Diuretics
  - 5.2.2.6. Nitrates
  - 5.2.2.7. Statins
- 5.2.3. Surgery
  - 5.2.3.1. Cardiac Resynchronization
  - 5.2.3.2. Coronary Artery Bypass Grafting
  - 5.2.3.3. Coronary Revascularization
  - 5.2.3.4. Heart Transplant
  - 5.2.3.5. Heart Valve Replacement

Chapter 6. Global Heart Failure Therapeutics Market Size & Forecasts by Type 2022-2032

6.1. Segment Dashboard
6.2. Global Heart Failure Therapeutics Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Diagnosis
- 6.2.2. Prognosis

Chapter 7. Global Heart Failure Therapeutics Market Size & Forecasts by Stage 2022-2032

7.1. Segment Dashboard
7.2. Global Heart Failure Therapeutics Market: Stage Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Stage A
- 7.2.2. Stage B
- 7.2.3. Stage C
- 7.2.4. Stage D

Chapter 8. Global Heart Failure Therapeutics Market Size & Forecasts by End User 2022-2032

8.1. Segment Dashboard
8.2. Global Heart Failure Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Clinic
- 8.2.2. Hospital
- 8.2.3. Medical Research Organization

Chapter 9. Global Heart Failure Therapeutics Market Size & Forecasts by Region 2022-2032

9.1. North America Heart Failure Therapeutics Market
- 9.1.1. U.S. Heart Failure Therapeutics Market
  - 9.1.1.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Type breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Stage breakdown size & forecasts, 2022-2032
  - 9.1.1.4. End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Heart Failure Therapeutics Market
  - 9.1.2.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.1.2.2. Type breakdown size & forecasts, 2022-2032
  - 9.1.2.3. Stage breakdown size & forecasts, 2022-2032
  - 9.1.2.4. End User breakdown size & forecasts, 2022-2032
9.2. Europe Heart Failure Therapeutics Market
- 9.2.1. U.K. Heart Failure Therapeutics Market
  - 9.2.1.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.2.1.2. Type breakdown size & forecasts, 2022-2032
  - 9.2.1.3. Stage breakdown size & forecasts, 2022-2032
  - 9.2.1.4. End User breakdown size & forecasts, 2022-2032
- 9.2.2. Germany Heart Failure Therapeutics Market
  - 9.2.2.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.2.2.2. Type breakdown size & forecasts, 2022-2032
  - 9.2.2.3. Stage breakdown size & forecasts, 2022-2032
  - 9.2.2.4. End User breakdown size & forecasts, 2022-2032
- 9.2.3. France Heart Failure Therapeutics Market
  - 9.2.3.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.2.3.2. Type breakdown size & forecasts, 2022-2032
  - 9.2.3.3. Stage breakdown size & forecasts, 2022-2032
  - 9.2.3.4. End User breakdown size & forecasts, 2022-2032
- 9.2.4. Spain Heart Failure Therapeutics Market
  - 9.2.4.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.2.4.2. Type breakdown size & forecasts, 2022-2032
  - 9.2.4.3. Stage breakdown size & forecasts, 2022-2032
  - 9.2.4.4. End User breakdown size & forecasts, 2022-2032
- 9.2.5. Italy Heart Failure Therapeutics Market
  - 9.2.5.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.2.5.2. Type breakdown size & forecasts, 2022-2032
  - 9.2.5.3. Stage breakdown size & forecasts, 2022-2032
  - 9.2.5.4. End User breakdown size & forecasts, 2022-2032
- 9.2.6. Rest of Europe Heart Failure Therapeutics Market
  - 9.2.6.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.2.6.2. Type breakdown size & forecasts, 2022-2032
  - 9.2.6.3. Stage breakdown size & forecasts, 2022-2032
  - 9.2.6.4. End User breakdown size & forecasts, 2022-2032
9.3. Asia-Pacific Heart Failure Therapeutics Market
- 9.3.1. China Heart Failure Therapeutics Market
  - 9.3.1.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.3.1.2. Type breakdown size & forecasts, 2022-2032
  - 9.3.1.3. Stage breakdown size & forecasts, 2022-2032
  - 9.3.1.4. End User breakdown size & forecasts, 2022-2032
- 9.3.2. India Heart Failure Therapeutics Market
  - 9.3.2.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.3.2.2. Type breakdown size & forecasts, 2022-2032
  - 9.3.2.3. Stage breakdown size & forecasts, 2022-2032
  - 9.3.2.4. End User breakdown size & forecasts, 2022-2032
- 9.3.3. Japan Heart Failure Therapeutics Market
  - 9.3.3.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.3.3.2. Type breakdown size & forecasts, 2022-2032
  - 9.3.3.3. Stage breakdown size & forecasts, 2022-2032
  - 9.3.3.4. End User breakdown size & forecasts, 2022-2032
- 9.3.4. Australia Heart Failure Therapeutics Market
  - 9.3.4.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.3.4.2. Type breakdown size & forecasts, 2022-2032
  - 9.3.4.3. Stage breakdown size & forecasts, 2022-2032
  - 9.3.4.4. End User breakdown size & forecasts, 2022-2032
- 9.3.5. South Korea Heart Failure Therapeutics Market
  - 9.3.5.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.3.5.2. Type breakdown size & forecasts, 2022-2032
  - 9.3.5.3. Stage breakdown size & forecasts, 2022-2032
  - 9.3.5.4. End User breakdown size & forecasts, 2022-2032
- 9.3.6. Rest of Asia Pacific Heart Failure Therapeutics Market
  - 9.3.6.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.3.6.2. Type breakdown size & forecasts, 2022-2032
  - 9.3.6.3. Stage breakdown size & forecasts, 2022-2032
  - 9.3.6.4. End User breakdown size & forecasts, 2022-2032
9.4. Latin America Heart Failure Therapeutics Market
- 9.4.1. Brazil Heart Failure Therapeutics Market
  - 9.4.1.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.4.1.2. Type breakdown size & forecasts, 2022-2032
  - 9.4.1.3. Stage breakdown size & forecasts, 2022-2032
  - 9.4.1.4. End User breakdown size & forecasts, 2022-2032
- 9.4.2. Mexico Heart Failure Therapeutics Market
  - 9.4.2.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.4.2.2. Type breakdown size & forecasts, 2022-2032
  - 9.4.2.3. Stage breakdown size & forecasts, 2022-2032
  - 9.4.2.4. End User breakdown size & forecasts, 2022-2032
- 9.4.3. Rest of Latin America Heart Failure Therapeutics Market
  - 9.4.3.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.4.3.2. Type breakdown size & forecasts, 2022-2032
  - 9.4.3.3. Stage breakdown size & forecasts, 2022-2032
  - 9.4.3.4. End User breakdown size & forecasts, 2022-2032
9.5. Middle East & Africa Heart Failure Therapeutics Market
- 9.5.1. Saudi Arabia Heart Failure Therapeutics Market
  - 9.5.1.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.5.1.2. Type breakdown size & forecasts, 2022-2032
  - 9.5.1.3. Stage breakdown size & forecasts, 2022-2032
  - 9.5.1.4. End User breakdown size & forecasts, 2022-2032
- 9.5.2. South Africa Heart Failure Therapeutics Market
  - 9.5.2.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.5.2.2. Type breakdown size & forecasts, 2022-2032
  - 9.5.2.3. Stage breakdown size & forecasts, 2022-2032
  - 9.5.2.4. End User breakdown size & forecasts, 2022-2032
- 9.5.3. Rest of Middle East & Africa Heart Failure Therapeutics Market
  - 9.5.3.1. Treatment breakdown size & forecasts, 2022-2032
  - 9.5.3.2. Type breakdown size & forecasts, 2022-2032
  - 9.5.3.3. Stage breakdown size & forecasts, 2022-2032
  - 9.5.3.4. End User breakdown size & forecasts, 2022-2032

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Abbott Laboratories
- 10.1.2. ABIOMED, Inc.
- 10.1.3. Amgen Inc.
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Alembic Pharmaceuticals Limited
- 10.3.2. AstraZeneca PLC
- 10.3.3. Bayer AG
- 10.3.4. Beckman Coulter, Inc.
- 10.3.5. Berlin Heart GmbH
- 10.3.6. Biosensors International Group, Ltd.
- 10.3.7. Biotronik SE & Co. KG
- 10.3.8. Boston Scientific Corporation
- 10.3.9. Bristol-Myers Squibb Company
- 10.3.10. Cardiol Therapeutics Inc.
- 10.3.11. Cipla Limited
- 10.3.12. Dr. Reddy's Laboratories Limited

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes